Human iPSC-derived microglia are genetically relevant to Alzheimer’s disease
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA532337 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR8881920_1.fastq.gz | Fastqsanger.gz | |||
| SRR8881920_2.fastq.gz | Fastqsanger.gz | |||
| SRR8881930_1.fastq.gz | Fastqsanger.gz | |||
| SRR8881930_2.fastq.gz | Fastqsanger.gz | |||
| SRR8881921_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 48 |
Similar Datasets
Project description:Microglia is a primary brain immune cell type that has been implicated in the pathogenesis of neurodegenerative disorders such as Alzheimer’s disease (AD) and neurodevelopmental disorders such as schizophrenia. Generating microglia from human induced pluripotent stem cells (hiPSC) has become an attractive approach to study the microglia-mediated causal mechanism of AD. Among other methods, Brownjohn et al. recently developed a particularly efficient and simple hiPSC-derived microglia (iMG) protocol. However, the transferability of this method to other labs, the transcriptomic similarity of these iMG to primary adult microglia, and their genetic relevance to AD remain unclear. With two hiPSC lines, we demonstrated that the Brownjohn method can efficiently give rise to iMG that were morphologically and functionally like microglia. Our pure iMG were also transcriptionally similar to previously reported iMG lines, as well as fetal and adult microglia. More importantly, we further showed the genetic relevance of iMG to AD using cell type-specific gene expression to partition disease heritability. Contrasting with neuronal and immune cell types, our iMG and several primary microglia and microglia-like cell types were all significantly enriched for AD relevant GWAS loci. These results supported the use of iMG as a valid human cellular model for understanding AD disease progression and a feasible mechanism for generation of AD patient-specific cell types for more precise in vitro analyses, and potentially more effective clinical care.
2020-05-14 | GSE129630 | GEO
Project description:To compare the proteome between PFN1 mutant and PFN1 WT iPSC-microglia under baseline conditions
2024-02-18 | PXD038943 | Pride
Project description:The accumulation of abnormal, non-mutated tau protein is a key pathological hallmark of Alzheimer’s disease (AD). Despite its strong association with disease progression, the mechanisms by which tau drives neurodegeneration in the intact brain remain poorly understood. Here, we selectively expressed non-mutated or mutated MAPT in neurons across the brain and observed neurodegeneration in the hippocampus, especially associated with non-mutated human tau. Single-nuclei RNA sequencing confirmed a selective loss of hippocampal excitatory neurons and revealed the upregulation of neurodegeneration-related pathways in the affected populations. The accumulation of phosphorylated tau was accompanied by cellular stress in neurons and reactive gliosis in multiple brain regions. Notably, the lifelong absence of microglia significantly and differentially influenced the extent of neurodegeneration in the hippocampus and thalamus. Therefore, our study established an AD-relevant tauopathy mouse model, elucidated both neuron-intrinsic and neuron-extrinsic responses, and highlighted a critical role for microglia in modulating tau-driven neurodegeneration.
2025-08-06 | GSE285945 | GEO
Project description:Microglia and neuroinflammation play an important role in the development and progression of Alzheimer’s disease (AD). Inositol polyphosphate-5-phosphatase D (INPP5D) is a myeloid-expressed gene genetically-associated with AD. Through unbiased analyses of RNA and protein profiles in INPP5D-disrupted iPSC-derived human microglia, we find that reduction in INPP5D activity is associated with molecular profiles consistent with disrupted autophagy and inflammasome activation. These findings are validated through targeted pharmacological experiments which demonstrate that reduced INPP5D activity induces the formation of the NLRP3 inflammasome, cleavage of CASP1, and secretion of IL-1 and IL-18. Further, in-depth analyses of human brain tissue across hundreds of individuals using a multi-analytic approach provides evidence that a reduction in function of INPP5D in microglia results in inflammasome activation in AD. These findings provide insights into the molecular mechanisms underlying microglia-mediated processes in AD and highlight the inflammasome as a potential therapeutic target for modulating INPP5D-mediated vulnerability to AD.
2024-01-26 | PXD046040 | Pride
Project description:Here we elucidate the effect of Alzheimer’s disease (AD)-predisposing genetic backgrounds, APOE4, PSEN1ΔE9 and APPswe, on functionality of human microglia. We present a physiologically relevant high-yield protocol for producing human microglia-like cells (iMGLs) from induced pluripotent stem cells. Differentiation is directed with small molecules through primitive erythromyeloid progenitors to recreate microglial ontogeny from yolk sac. The iMGLs express microglial signature genes and respond to ADP with intracellular Ca2+ release distinguishing them from macrophages. Using 16 iPSC lines from healthy donors, AD patients and isogenic controls, we reveal that the APOE4 genotype has a profound impact on several aspects of microglial functionality whereas PSEN1ΔE9 and APPswe mutations trigger minor alterations. The APOE4 genotype impairs phagocytosis, migration and metabolic activity of iMGLs but exacerbates their cytokine secretion. This indicates that APOE4 iMGLs are fundamentally unable to mount normal microglial functionality in AD.
2019-10-08 | GSE135707 | GEO
Project description:Alzheimer’s disease (AD) is the most common form of dementia and risk-influencing genetics implicates microglia and neuroimmunity in the pathogenesis of AD. iPSC-microglia are increasingly used as a model of AD but the relevance of common immune stimuli to model AD is unclear. We performed a detailed cross-comparison over time on the effects of combinatory stimulation of iPSC-microglia, and in particular their relevance to AD. We used single cell RNA-seq to measure the transcriptional response of iPSC-microglia after 24 and 48h of stimulation with PGE2 or LPS+IFN-γ either alone or in combination with ATPγS. We observed a shared core transcriptional response of iPSC-microglia to ATPγS and to LPS+IFN-γ, suggestive of a convergent mechanism of action. Across all conditions we observed a significant overlap and functional links to genes that change their expression levels in human microglia from AD patients. Using a data-led approach, we identify a common axis of transcriptomic change across AD genetic mouse model microglia and show that only LPS provokes a transcriptional response along this axis in mouse microglia and LPS+IFN-γ in human iSPC-microglia.
2021-10-23 | GSE186301 | GEO
Project description:Iron accumulation in microglia has been observed in Alzheimer’s disease and other neurodegenerative disorders and is thought to contribute to disease progression through various mechanisms including neuroinflammation. To study the interaction between iron accumulation and inflammation, we treated human induced pluripotent stem cell-derived microglia (iPSC-MG) with an increasing concentration of iron, in combination with inflammatory stimuli such as interferon gamma and amyloid β, and performed RNA sequencing.
| EGAS00001006112 | EGA
Project description:RNA-seq of genetically engineered mouse microglia sorted into populations.
2022-04-06 | GSE196174 | GEO
Project description:RNA-seq of genetically engineered mouse microglia
| PRJNA803528 | ENA
Project description:Many studies have sought to circumvent the protective qualities of the blood brain barrier to deliver therapeutic proteins to the brain for the treatment of neurodegenerative diseases. Yet, brain specific uptake, peripheral toxicity, off-target effects, and repeated dosing continue to present considerable challenges. As proof of principle, we sought to determine whether human iPSC-microglia (iMG) could be genetically engineered ex vivo to enable pathology-responsive delivery of amyloid-targeting proteins to the brain. Human iPSCs were CRISPR-edited to express the beta-amyloid degrading enzyme neprilysin (NEP) or secreted neprilysin (sNEP) under control of the endogenous CD9 promoter, a microglial gene that is specifically upregulated in plaque-associated microglia. Following adult-transplantation into xenotolerant, amyloid-accumulating mice (5x-MITRG), beta-amyloid peptides, synaptic markers, and off-target substrate levels were examined. To further determine whether increased engraftment of therapeutic microglia could provide additional disease-modifying efficacy, sNEP iMGs were further modified to confer resistance to CSF1R antagonists, enabling brain-wide engraftment of human microglia. Amyloid pathology and synaptic, inflammatory, and neurodegeneration biomarkers were then assessed. We demonstrate that microglia can be engineered to enable pathology-responsive delivery of therapeutic proteins to the brain. NEP and sNEP xenografted microglia reduced levels of amyloid peptides and oligomers, prevented pathology-associated reductions in synaptic markers, and lowered astrogliosis within the hippocampus and overlying cortex of 5x-MITRG mice without off-target degradation. Surprisingly, sNEP delivery by microglia adjacent to the injection site alone was sufficient to achieve almost all disease-modifying outcomes as effectively as CNS-wide sNEP-microglia engraftment. However, significant reductions in amyloid pathology, dystrophic neurites, and perineuronal nets within the plaque-dense subiculum of 5x-MITRG mice was only achieved following CNS-wide microglial replacement. Taken together, these results demonstrate that human microglia can be engineered as a promising new immune cell therapeutic platform to provide widespread and pathology-responsive delivery of biological therapeutics for the treatment of neurodegenerative disease.
2025-07-01 | GSE282917 | GEO